Key result
Cilostazol and naftidrofuryl demonstrated protective effects against ischemia-reperfusion injury, with cilostazol significantly affecting total oxidant levels in the heart (p < 0.01).
Why the study?
Naftidrofuryl and cilostazol have proven efficacy for claudication in peripheral vascular disease, but their comparative effects on ischemia-reperfusion injury across various tissues required evaluation.
Does cilostazol or naftidrofuryl reduce oxidative stress in an experimental acute ischemia-reperfusion model in rats?
RCT (n=40)
randomly divided
Does cilostazol or naftidrofuryl reduce oxidative stress in an experimental acute ischemia-reperfusion model in rats?
p-value: p=<0.01
In a rat model of ischemia-reperfusion injury, cilostazol and naftidrofuryl demonstrated tissue-specific protective effects against oxidative stress, with cilostazol showing particular benefit in the heart, muscle, and kidney.
Should not change clinical practice in peripheral vascular disease; leaves open effects of these agents on ischemia-reperfusion injury.
INTRODUCTION: Naftidrofuryl and cilostazol are drugs with proven efficacy in the treatment of claudication in peripheral vascular disease. In this experimental study, we evaluated the effects of naftidrofuryl and cilostazol in ischemia-reperfusion (IR) injury on various tissues. MATERIALS AND METHODS: 40 male albino Wistar rats (8-12 weeks old, 250-350 g.) are randomly divided into 4 groups: Control (Group 1), sham (group 2), cilostazol pre-treatment (group 3), naftidrofuryl pre-treatment (group 4). During 21 days placebo is given to group 2, 12 mg/kg/day cilostazol is given to group 3, 50 mg/kg/day naftidrofuryl is given to group 4 orally. Ischemia and reperfusion are induced at the lower hind limb in Groups 2, 3 and 4. Ischemic muscle, kidney, liver, heart, brain and blood samples are obtained. The total antioxidant capacity, oxidant levels and oxidative stress index are studied for each group. RESULTS: Both drugs have protective effects of remote organ injury following IR. Systemic effects are similar to each other, both have protective effects of IR injury. It showed no statistical significance in the total antioxidant capacity. Total oxidant levels are significantly affected by cilostazol in the heart (p < 0.01) and by naftidrofuryl in the liver (p < 0.01). The effect on oxidative stress was only significant with cilostazol on the heart (p < 0.01). CONCLUSION: Cilostazol and naftidrofuryl had beneficial effects in all tissues against tissue damage caused by IR injury. In ischemic muscle, kidney and heart cilostazol had improved outcomes comparing to naftidrofuryl. Naftidrofuryl had benefits over cilostazol in liver tissue.
No takes yet. Share an insight, caveat, or question.
Gülaştı et al. (2020) conducted an RCT in Ischemia-reperfusion (IR) injury (n=40). Cilostazol and Naftidrofuryl vs. Placebo/Sham and Control was evaluated on Total antioxidant capacity, oxidant levels and oxidative stress index (p=<0.01). Cilostazol and naftidrofuryl demonstrated protective effects against ischemia-reperfusion injury, with cilostazol significantly affecting total oxidant levels in the heart (p < 0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: